Dr Hillary Keenan

Senior Director, Global Evidence and Outcomes, Takeda Pharmaceuticals, Cambridge, MA, USA

Hillary Keenan, Ph.D., M.S. is an epidemiologist who spent two decades studying the effects of dysglycemia and vascular dysfunction in the population. Her work has focused on using translational approaches to better understand disease patterns and identify mechanism specific targets. She gained her MS in epidemiology at the University of Massachusetts, Amherst and worked with the Centers for Disease Control and Prevention in the Branch of Sexually Transmitted Diseases, as well as the Massachusetts Department of Public Health on social health issues.

Dr. Keenan began her career in genetic epidemiology and translational medicine at the University of Pittsburgh while earning her doctorate in molecular epidemiology. As a post- doctoral fellow, she continued her work in genetics and began her work identifying both endogenous and lifestyle factors which protect from complications associated with hyperglycemia. A significant portion of this work was done examining individuals who have lived 50 or more years with type 1 diabetes at the Joslin Diabetes Center where she remained on faculty for 14 years before joining industry. Currently, she works to demonstrate the relative effectiveness of new therapies and accelerating access for patients.

Updated 22 November 2024